Salubris Innovative Drug Discovery Center

Founded in 1998, ShenzhenSalubris PharmaceuticalsCo. is a comprehensive listed pharmaceutical group that integrates the research and development, production, and sales of innovative pharmaceutical products. Focusing on the treatment of chronic diseases such as cardiovascular and cerebrovascular diseases, the company boasts a rich and highly innovative product pipeline, with over 70 ongoing research projects and the ability to achieve approvals for more than two innovative products each year.

A leading companyin China’s cardiovascular and cerebrovascular therapeutic sector, Salubris Pharmaceuticals is also Shenzhen’s largest prescription drug company and operates dual headquarters in Shenzhen and Futian. Since its establishment, the company has achieved an industrial output value of nearly 60 billion yuan and paid more than 8.5 billion yuan in taxes. In the past three years, it has contributed an output value of 10.44 billion yuan and paid over 800 million yuan in taxes in Shenzhen.

Its research and development centers are located in Shenzhen (Hetao and Pingshan), Beijing, Chengdu, Suzhou and America (Maryland). Over the past five years, the cumulative R&D investment of Salubris Pharmaceuticalshas reached 4 billion yuan. In 2022, the company's R&D investment was 917 million yuan, and in the first half of 2023, the R&D investment grew 17.1% year on year to 498 million yuan. The company has won the China Patent Gold Award three times and has also been awarded the titles of National Enterprise Technology Center, National High-tech Enterprise, and National Technology Innovation Demonstration Enterprise. Taking the lead in establishing the Guangdong-Hong Kong-Macao Greater Bay Area Small Molecule Drug Innovation Center, Salubris Pharmaceuticals is now the chairman unit of the Shenzhen Biomedical Industry Alliance.

The Salubris Innovative Drug Discovery Center in Shenzhen.

The Salubris Innovative Drug Discovery Center is located at Floor 4, Zone A, International Biomedical Industrial Park (Phase II), Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. It mainly conducts exploratory research on innovative and cutting-edge products.